Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

17 clinical studies listed.

Filters:

Survival

Tundra lists 17 Survival clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT06563245

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

Generally, pediatric patients tolerate acute toxicities but are vulnerable to late effects. Thus, increasing chemotherapy intensity to achieve more rapid complete early response to limit radiation therapy is worth testing. In this CCCG-HL-2024 study, Brentuximab vedotin (Bv) was used to replace VCR and bleomycin in the ABVE-PC regimen in the previous CCCG-HD-2018 study, respectively, to form a Bv-AEPC regimen for the treatment of newly diagnosed classic Hodgkin lymphoma (cHL) in children, adolescents and young adults. On the premise of maintaining a 4-year event free survival (EFS)\>90% in the low-, intermediate-and high-risk groups, increase the early assessment complete response rate (the overall early complete response rate increased by 20%, that is, from 54.0% to 74.0%) to further reduce the proportion of children receiving radiotherapy to benefit them.

Gender: All

Ages: 2 Years - 35 Years

Updated: 2026-03-19

Classical Hodgkin Lymphoma
Child
Adolescent
+6
NOT YET RECRUITING

NCT07161167

Changes in Body Composition of Patients With Obesity Related Tumors and Their Impact on Clinical Outcomes: a Multicenter Prospective Cohort Study

Over the past 20 years, China's obesity rates have surged, increasing cancer burden. Obesity links to 13 cancers via metabolic effects of visceral fat and insulin resistance, while sarcopenic obesity (BMI-independent) may worsen outcomes. Traditional BMI lacks precision; advanced methods (e.g., BIA/CT) are needed. Existing studies show inconsistent results, possibly due to heterogeneity. This multicenter prospective cohort study uses imaging to assess body composition changes (fat/muscle) in obesity-related tumors and their impact on survival, recurrence, and quality of life, and explore the underlying mechanism.

Gender: All

Ages: 18 Years - Any

Updated: 2025-09-08

1 state

Obesity Rekated Cancer
Body Composition Changes
Survival
+1
ACTIVE NOT RECRUITING

NCT03624595

Low-dose Dexmedetomidine and Postoperative Delirium After Cardiac Surgery

Delirium is an acutely occurred and fluctuating cerebral dysfunction characterized with inattention, altered consciousness, cognitive decline and/or abnormal perception. It is common in the elderly after cardiac surgery and is associated with worse outcomes. Causes leading to delirium are multifactorial but sleep disturbances remains an important one. In previous studies, sedative-dose dexmedetomidine improves sleep quality in ICU patients with mechanical ventilation; and low-dose dexmedetomidine improves sleep quality in postoperative patients without mechanical ventilation. In recent studies of elderly after noncardiac surgery, night-time infusion of low-dose dexmedetomidine reduces delirium and improves 2-year survival. The investigators hypothesize that, for elderly patients after cardiac surgery, night-time infusion of dexmedetomidine may also improve sleep quality, reduce delirium development and improve 2-year survival.

Gender: All

Ages: 60 Years - 90 Years

Updated: 2025-04-09

1 state

Cardiac Surgery
Cardiopulmonary Bypass
Dexmedetomidine
+2
RECRUITING

NCT06884839

Tumor Deposits in Colorectal Cancer and Its Prognostic Value in Survival and Metastasis

This study aims to evaluate the tumor deposits in colorectal cancer and its prognostic value in survival and metastasis

Gender: All

Ages: 18 Years - Any

Updated: 2025-03-19

Tumor Deposits
Colorectal Cancer
Prognosis
+2
RECRUITING

NCT04962672

Anesthesia Induced Brain Cancer Survival (ABC Survival): A Feasibility Study

Cancer is a leading cause of death worldwide. It is estimated that approximately 55,000 Canadians are surviving with brain tumors. It is projected that around 3000 persons will be diagnosed with brain and spinal cord tumors, and approximately 75 percent patients will not survive. Out of all brain cancers, high-grade gliomas \[Glioblastoma Multiforme (GBM)\] impose highest morbidity and mortality. Therefore, it is important to explore ways in which Investigators can improve and prolong the lives of patients suffering from brain cancers, particularly high-grade glioma, which is the most common and aggressive primary brain tumor. So far the Investigators know that the surgery, chemotherapy and radiotherapy are the three corner stones management options for these patients, and majority of the research have been conducted on these three major domains. Therefore, it is imperative to explore the other variables those may impact survival characteristics. One of the integral variables of the brain cancer surgery is anesthesia. Interestingly, the role of anesthetics was explored in some other non-brain solid organ tumor surgeries. It is observed that out of the two main types of anesthesia \[one is through intravenous (propofol) and other one is gaseous (sevoflurane)\], intravenous based anesthesia maintenance regime may delay the cancer progression and prolong the recurrence free period. In addition, two very large retrospective studies with approximately 11,000 and 18,000 patients respectively, showed that as compared to gaseous (volatile anesthetics) based, intravenous (propofol) based anesthesia conferred some protection against cancer progression and was also associated with lesser overall mortality. The exact nature of these protective mechanisms is not known but in animal and other laboratory-based experiments, propofol seems to inhibit cancer formation steps, delays inflammation and provide protection from cancer cell growth. This is a feasibility study for knowing various aspects of workflow; recruitment characteristics of participants and various obstacles in implying anesthesia based protocols so that the Investigators can conduct a well-designed multicenter international randomized study.

Gender: All

Ages: 18 Years - Any

Updated: 2025-01-31

1 state

Anesthesia
Brain Cancer
Survival
ENROLLING BY INVITATION

NCT06788054

Intradialysis Exercise Functional Capacity, Body Composition and Survival in Hemodialysis Patients

Chronic kidney disease and renal replacement treatments (hemodialysis, peritoneal dialysis, kidney transplant) produce various alterations at the level of muscle, bones, fat content and the heart; can alter physical capabilities such as muscle strength, resistance to climb a step repeatedly intensely, and the ability to move the joints freely, in addition to producing an increase or decrease in weight and alterations in its distribution (for example, decreasing muscle and increase fat). The above, added to the particular factors of hemodialysis such as the reduction in daily time to exercise due to the sessions, or the fatigue after it, can together generate greater repercussions on functional capacity and thus increase the risk of suffering from cardiovascular problems. and accelerate the evolution of the disease. Therefore, this study aims to determine the effect of a 12-week supervised physical exercise program during hemodialysis on strength and ability to move, the amount of fat and muscle in the body, as well as bone wear. ; and compare these results with a group of patients who do not perform supervised exercise. In addition, it will be determined how exercise can act in the long term, preventing the risk of hospitalization and death due to cardiovascular causes. The above is useful in order to establish recommendations and protocols that help us increase the quality of life and survival of the person.

Gender: All

Ages: 18 Years - 50 Years

Updated: 2025-01-22

1 state

Hemodialysis
Kidney Disease, Chronic
Physical Activity
+4
RECRUITING

NCT06627634

Radical Surgery for Advanced Gastric- or GEJ-cancer With Oligometastatic Dissmination to the Liver

Offering treatment with potential to cure for participants with no such offer in today's standard treatment options, by offering metastatectomia and standard treatment with intention to cure i.e., neoadjuvant chemotherapy and gastrectomy for participants with gastric- og gastroeusofageal junction cancer. Including 20 participants from all 4 centres in Denmark able to perform the surgical procedures in question. Endpoints: 2-year overall survival.

Gender: All

Ages: 18 Years - Any

Updated: 2024-10-04

1 state

Survival
NOT YET RECRUITING

NCT06147180

Comparison of Long-term Survival and Quality of Life After Minimally Invasive Esophagectomy Versus Open Esophagectomy

To analyze and compare the long-term recurrence-free survival rate, overall survival rate and quality of survival after minimally invasive esophagectomy and open esophagectomy, and to conduct subgroup analysis according to the type of esophageal cancer and pathological stage, etc., and to explore more deeply the differences between minimally invasive esophagectomy and open esophagectomy in terms of the benefits for different types of patients, so as to provide reference for the selection of the clinical surgical methods. We will also use the available data to analyze the influence of other factors on patients\' long-term survival after surgery.

Gender: All

Updated: 2023-11-27

1 state

Esophagus Cancer
Esophagectomy
Quality of Life
+1
NOT YET RECRUITING

NCT06119373

Incremental PD With Single Icodextrin Exchange

Objectives: To investigate the efficacy and safety of single daily icodextrin exchange for initiation of incremental peritoneal dialysis (PD). Subjects: Seventy-two incident PD patients. Methods: A single-center randomized controlled trial. Primary outcome: Change in residual kidney function in 48 weeks after recruitment.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2023-11-08

Peritoneal Dialysis Complication
Residual Kidney Function
Survival
+1
NOT YET RECRUITING

NCT06049758

D2 Versus D3 Dissection in Laparoscopic Right Hemicolectomy

Evaluating the differences between D2 and D3 lymphadenectomy in laparoscopic right hemicolectomy in patients with right cancer colon post-operative outcome, intra-operative blood transfusion, post-operative ICU admission, anastomotic leakage, lymph node harvesting in the final specimen, and six months follow up and overall survival time after 5-years

Gender: All

Updated: 2023-09-22

Blood Loss
Intensive Care
Anastomotic Leakage
+3
RECRUITING

NCT04280822

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains unknown. One of our objectives is to evaluate whether the neo-adjuvant immunochemotherapy Toripalimab (JS001) with cisplatin and paclitaxel followed by right thoracic approach esophagectomy with total 2-field lymph node dissection improves the overall survival of thoracic esophageal cancer patients versus neo-adjuvant chemotherapy.

Gender: All

Ages: 18 Years - 75 Years

Updated: 2022-10-04

1 state

Esophageal Cancer
Surgery
Neoadjuvant Treatment
+1
NOT YET RECRUITING

NCT05285332

Classified Treatment Strategy for De-novo Metastatic Breast Cancer After Systemic Adjuvant Therapy

For patients with de novo stage IV breast cancer, the current debate is whether local surgery can improve the survival of patients. There is no clinical study on the classification after systemic treatment of de novo stage IV breast cancer patients. In fact, the clinical stage of tumor can change with the change of treatment. For example, the stage Ⅲ of locally advanced breast cancer can down-staging to the stage Ⅱ after systemic treatment. Similarly, patients with stage Ⅳ can down-staging to stage Ⅱ or stage Ⅲ after systemic treatment. At this time, the patient can receive surgical treatment. Therefore, this study is to first treat de novo stage IV breast cancer patients with systemic treatment, according to the response after systemic treatment to give different treatment measures(surgery or continued systemic treatment). The investigators hope that this study will provide new ideas for the treatment of de novo stage IV breast cancer and other de novo stage IV cancers.

Gender: FEMALE

Ages: 18 Years - 75 Years

Updated: 2022-07-19

Breast Neoplasms
Treatment
Metastatic Breast Cancer
+1
NOT YET RECRUITING

NCT04845490

Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy

This study is a prospective, randomized, comparative clinical trial conducted by Wuhan Union Hospital and aim to compare the therapeutic effects of Mitomycin and Lobaplatin in the treatment of advanced colorectal cancer patients with radical surgery combined with hyperthermic intraperitoneal chemotherapy

Gender: All

Ages: 18 Years - 75 Years

Updated: 2022-02-21

Colorectal Cancer
Chemotherapy Effect
Surgery
+2
RECRUITING

NCT04519905

Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)

So far, there is no specific clinical guideline for elderly patients (\>75 yr) with esophageal squamous cell carcinoma (ESCC). Patients with locally advanced ESCC were enrolled and randomly assigned to either definitive radiotherapy group (61.2Gy/34Fx) or the chemoradiotherapy group (50.4Gy/28Fx;Paclitaxel plus carboplatin). The primary end point was 3-year overall survival (OS). The second end points included life quality, radiation side effects and 3-yr cancer specific survival.

Gender: All

Ages: 76 Years - Any

Updated: 2021-11-02

2 states

Esophageal Squamous Cell Carcinoma
Chemoradiotherapy
Survival
RECRUITING

NCT04996732

Long-term Survivorship of Discharged Patients With Malignant Tumor Based on Single-institutional Cancer Registry

Real-world studies on long-term prognosis in patients who underwent anti-tumor treatments during hospitalization from a hospital-based cancer registry in china.

Gender: All

Updated: 2021-08-09

Neoplasms
Survival
Surgery
+2
NOT YET RECRUITING

NCT04890522

An Open-label, Multicentre, Phase II/III RCT of PFLL Versus GP Combined With JS001 as the First-line Therapy for mNPC

The treatment of distant metastasis is a key challenge for nasopharyngeal carcinoma because of poor outcomes, among which, chemotherapy is the cornerstone. However, many studies reported the use of different chemotherapy regimens to prolong the survival of metastatic nasopharyngeal carcinoma, while few of them focused on how to reduce the side effects of chemotherapy or improve the life quality of patients. Blocking the immune checkpoint is one of the effective strategies of tumor immunotherapy. Thus, we sought to find a proper chemotherapy regimen combined with PD-1 antibody JS001.

Gender: All

Ages: 18 Years - 60 Years

Updated: 2021-05-18

1 state

Nasopharyngeal Carcinoma
Metastasis
Chemotherapy
+2
RECRUITING

NCT03920033

Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy

Patients with a biochemical recurrence after radical prostatectomy for moderate- or high- risk prostate cancer are randomly assigned to hypofractionated, accelerated high dose radiation therapy group (65 Gy, 26 fractions) and a control group of standard treatment group (66 Gy, 33 fractions). The criteria for stratification at randomization include 1) risk groups, 2) androgen deprivation therapy, and 3) PSA before salvage radiation therapy, which affect biochemical recurrence. It is expected that hypofractionated, accelerated high dose radiation therapy will have a superiority in terms of biochemical control to conventional radiation therapy, and the present study would like to confirm this. In addition, we aimed to evaluate and compare the toxicity and quality of life index of two radiation therapy regimens.

Gender: MALE

Ages: 20 Years - Any

Updated: 2021-01-20

Prostate Cancer
Biochemical Recurrence
Radiation
+5